Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Automatic three-year exclusivity for Rx-to-OTC switches urged by NDMA.

This article was originally published in The Tan Sheet

Executive Summary

Rx-TO-OTC SWITCHES AUTOMATIC THREE-YEAR EXCLUSIVITY URGED BY NDMA in written comments to the April 11 Senate Labor & Human Resources Committee hearing on FDA reform ("The Tan Sheet" April 14, p. 15). Among its requests, the Nonprescription Drug Manufacturers Association asks for a congressional "declaration that the grant of three-year exclusivity in current law shall be the general rule for applications to switch a drug from prescription to nonprescription status, to ensure the continued vitality of the important OTC switch movement."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086952

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel